KPS-0373
Sponsors
Kissei Pharmaceutical Co., Ltd.
Conditions
SCDSpinocerebellar Degeneration
Phase 2
Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
CompletedNCT00863538
Target: 40Updated: 2010-02-03
A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
CompletedNCT01004016
Target: 20Updated: 2010-09-28
A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
CompletedNCT01384435
Target: 200Updated: 2012-12-03
Phase 3
An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
CompletedNCT02889302
Start: 2016-11-15End: 2018-03-31Updated: 2018-12-14
Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration
Active, not recruitingNCT07040137
Start: 2025-08-15End: 2027-03-31Target: 142Updated: 2026-09-04